11. A biotechnology company called Intercept Pharmaceutical, focused on development of drug for l...
11. A biotechnology company called Intercept Pharmaceutical, focused on development of drug for liver fibrosis disease called NASH announced that its experimental drug called OCA was experimented on 930 patients (465 in placebo group and 465 in 25 mg OCA group ) and the patients were followed up for 18 months. The result is as follows: 23.1% patients taking 25 mg of OCA versus 11.1% of placebo patients showed fibrosis improvement Serious adverse effects of 28% (OCA group) versus 19% (placebo group) were also observed. . a. Find the odds ratio of the benefit of OCA b. Find the risk ratio of the adverse effect of OCA
11. A biotechnology company called Intercept Pharmaceutical, focused on development of drug for liver fibrosis disease called NASH announced that its experimental drug called OCA was experimented on 930 patients (465 in placebo group and 465 in 25 mg OCA group ) and the patients were followed up for 18 months. The result is as follows: 23.1% patients taking 25 mg of OCA versus 11.1% of placebo patients showed fibrosis improvement Serious adverse effects of 28% (OCA group) versus 19% (placebo group) were also observed. . a. Find the odds ratio of the benefit of OCA b. Find the risk ratio of the adverse effect of OCA